Arab Press

بالشعب و للشعب
Friday, Jun 20, 2025

Chinese drug firm says employees have been given Covid-19 vaccines

Chinese drug firm says employees have been given Covid-19 vaccines

Company says almost all those offered its CoronaVac under the country’s emergency use scheme agreed to receive the injections.

Almost all the employees of a Chinese drug company and their families have been given its experimental coronavirus vaccine, the firm said on Sunday.

The CoronaVac vaccine developed by Sinovac Biotech, is currently undergoing phase three clinical trials.

Company spokesman Liu Peicheng confirmed that the around 3,000 employees and families had been offered the drug on a voluntary basis under China’s emergency use scheme.

Sinovac’s coronavirus vaccine production line, which has an annual output capacity of more than 300 million doses, started operations at the end of last month.


Sinovac’s products on display at a trade fair.


The vaccine’s entry into the mass market is subject to the results of the latest trials but the company’s chief executive Yin Weidong said he expected its use to be approved as soon as the end of the year.

In July, China approved the emergency use of vaccines for specific groups who were deemed to be at high risk of exposure, including medical personnel and border officials.

Beijing was the first city in China to start the emergency use programme and tens of thousands of people – including workers at the Xinfadi food market, which was at the centre of the capital’s last major outbreak in June – have been given the Sinovac vaccine.

“It will also prevent repeated epidemics in the coming autumn and winter seasons,” Yin told the China International Fair for Trade in Services in Beijing.

“If there is one person infected in this venue, it will affect hundreds of people. The strong control strategy in China needs to be improved, and improvement needs to rely on vaccines.

“The pricing [of the vaccine] is unknown at the moment, but not as high as people expect, it should be an acceptable price for everyone.”

Meanwhile, Zhang Yinan, deputy general marketing manager at China National Biotec Group (CNBG), also said that she had been given her company’s vaccine.

“After animal testing, I’m willing to try the company’s product to see if it’s safe and effective, and there are 150 employees like me who have been inoculated,” she said at the trade fair.


Sinovac and CNBG are currently carrying out large-scale trials abroad as they race to get their vaccines onto the market.

CNBG is expected to complete its phase three clinical trial, which has seen more than 35,000 people given the vaccine in the United Arab Emirates, in November.

“The UAE has a purchase intent [agreement] with CNBG and we can’t disclose the exact figure, nor the pricing”, Zhang said.

Sinovac says it has received orders from a number of countries and is currently conducting phase three trials in Turkey, Bangladesh, Brazil and Indonesia.

In late August, Sinovac and PT Bio Farma, a state-owned Indonesian pharmaceutical company, signed a preliminary agreement for the purchase and supply of CoronaVac, which Liu described as the “largest publicly reported order to date for a Chinese vaccine company”.

The agreement provides for the supply of 40 million doses of semi-finished CoronaVac products between November and March, with further sales likely throughout next year. Bio Farma will package the vaccines and supply them to customers in Indonesia.

Sinovac has urged the authorities in different countries to ensure the vaccine can be registered more quickly.


China National Biotec Group’s vaccine is undergoing a large-scale trial in the UAE.


“For example, if the study we did in Brazil is accepted by other countries in South America, the vaccine can be registered and we can supply it to more countries.” Yin said.

“We call on more countries to accept the results of our current clinical studies and approve a safe and effective vaccine for marketing as soon as possible. Of course, the biggest market for vaccines, the biggest demand, and the biggest challenges, are all in China.”

Sinovac claimed that no serious adverse reactions have been observed in the phase three clinical trials, indicating that the vaccine is safe. “The adverse reactions observed were mainly local pain at the injection site, followed by fatigue and weakness, and local swelling, all of which were transient,” Liu said, “Only very few have fever and allergic reactions.”

Last month both Sinovac and CNBG warned consumers not to fall for online scams in which advertisers are offering Covid-19 vaccines for sale.

Newsletter

Related Articles

Arab Press
0:00
0:00
Close
16 Billion Login Credentials Leaked in Unprecedented Cybersecurity Breach
Senate hearing on who was 'really running' Biden White House kicks off
G7 Leaders Fail to Reach Consensus on Key Global Issues
Mass exodus in Tehran as millions try to flee following Trump’s evacuation order
Iranian Military Officers Reportedly Seek Contact with Reza Pahlavi, Signal Intent to Defect
China's Iranian Oil Imports Face Disruption Amid Escalating Middle East Tensions
Trump Demands Iran's Unconditional Surrender Amid Escalating Conflict
Israeli Airstrike Targets Iranian State TV in Central Tehran
President Trump is leaving the G7 summit early and has ordered the National Security Council to the Situation Room
Netanyahu Signals Potential Regime Change in Iran
Analysts Warn Iran May Resort to Unconventional Warfare
Iranian Regime Faces Existential Threat Amid Conflict
Energy Infrastructure Becomes War Zone in Middle East
Iran Conducts Ballistic Missile Launches Amid Heightened Tensions with Israel
Iran Signals Openness to Nuclear Negotiations Amid Ongoing Regional Tensions
Shock Within Iran’s Leadership: Khamenei’s Failed Plan to Launch 1,000 Missiles Against Israel
UK Deploys Jets to Middle East Amid Rising Tensions
Exiled Iranian Prince Reza Pahlavi Urges Overthrow of Khamenei Regime
Wreck of $17 Billion San José Galleon Identified Off Colombia After 300 Years
Iran Launches Extensive Missile Attack on Israel Following Israeli Strikes on Nuclear Sites
Israel Issues Ultimatum to Iran Over Potential Retaliation and Nuclear Facilities
Coinbase CEO Warns Bitcoin Could Supplant US Dollar Amid Mounting National Debt
Trump to Iran: Make a Deal — Sign or Die
Operation "Like a Lion": Israel Strikes Iran in Unprecedented Offensive
Israel Launches 'Operation Rising Lion' Targeting Iranian Nuclear and Military Sites
Israeli Forces Intercept Gaza-Bound Aid Vessel Carrying Greta Thunberg
IMF Warns of Severe Global Trade War Impacts on Emerging Markets
Syria to Reconnect to Global Economy After 14 Years of Isolation
Saudi Arabia Faces Uncertainty Over Succession After Mohammed bin Salman
Israel Confirms Arming Gaza Clan to Counter Hamas Influence
Majority of French Voters View Macron's Presidency as a Failure
U.S. Reduces Military Presence in Syria
Trump Demands Iran End All Uranium Enrichment in Nuclear Talks
Iran Warns Europe Against Politicizing UN Nuclear Report
Businessman Mauled by Lion at Luxury Namibian Lodge
Paris Saint-Germain's Greatest Triumph Is Football’s Lowest Point
OPEC+ Agrees to Increase Oil Output for Third Consecutive Month
Turkey Detains Istanbul Officials Amid Anti-Corruption Crackdown
Meta and Anduril Collaborate on AI-Driven Military Augmented Reality Systems
EU Central Bank Pushes to Replace US Dollar with Euro as World’s Main Currency
European and Arab Ministers Convene in Madrid to Address Gaza Conflict
Head of Gaza Aid Group Resigns Amid Humanitarian Concerns
U.S. Health Secretary Ends Select COVID-19 Vaccine Recommendations
Trump Warns Putin Is 'Playing with Fire' Amid Escalating Ukraine Conflict
India and Pakistan Engage Trump-Linked Lobbyists to Influence U.S. Policy
U.S. Halts New Student Visa Interviews Amid Enhanced Security Measures
Trump Administration Cancels $100 Million in Federal Contracts with Harvard
SpaceX Starship Test Flight Ends in Failure, Mars Mission Timeline Uncertain
King Charles Affirms Canadian Sovereignty Amid U.S. Statehood Pressure
Iranian Revolutionary Guard Founder Warns Against Trusting Regime in Nuclear Talks
×